A simple cheek swab test tells you about the possible adverse effects of any medication based on DNA and helps you customize treatment plan for a patient.
Despite the consideration of patient characteristics, adverse reactions to prescription medications plague our country. Genetic factors can account for 20 to 95 percent of patient variability. The addition of next generation genetic testing provides physicians with the personalized data needed to optimize medication absorption, and metabolism. PGX offers actionable steps to perfect individual patient dosing.
Our solutions transform pharmacogenetic test results into concise, actionable reports for physicians. Reports incorporate the latest guidance from scientific groups (e.g., the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)), governments (e.g., the Federal Drug Administration (FDA) and the European Medicines Agency (EMA)), and leading-edge science.
Evidence continues to build patient-supporting individualized pain management dosing for many Schedule II drugs leading to proper analgesic. PGX testing provides pain management clinicians a direct way to mitigate side effects and improve patients medication response.
CYP1A2 | COMT | CYP2C19 | CYP2C9 | CYP2D6 OPRM1
Identify inherited conditions that cause coagulation, increase thrombosis risk, and help determine the best anti-coagulation therapy. Studies show that patients with Factor V mutation have a higher post-surgery clot risk. If genetic testing is done before hand, this and other situations can be prepped for and can help the doctor understand a patient’s unique needs.
CYP2D6 | VKORC1 | CYP2C9 | MTHFR | Factor II | Factor V
COMT | CYP1A2 | CYP2C19 | CYP2B6 | CYP2D6 | MTHFR | OPRM1
Allows physicians to understand the risk of thrombosis, obstetric complications and thrombophilia in family members of affected individuals.
Factor II | Factor V | MTHFR
With heart diseases being the number one cause of death in America and 2.8 billion Rx prescribed for out patients, the call to personalized dosage is staring physicians in the face. This test helps physicians determine therapeutic change for lasting patient health in the expanding field of cardiovascular health.
APOE | CYP3A4 | CYP2C19 | CYP2C9 | CYP2D6 | Factor II | Factor V VKORC1 | SLC01B1 MTHFR